The consensus among analysts is that Sangamo Therapeutics, Inc. (SGMO) is an Overweight stock at the moment, with a recommendation rating of 2.2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 4 out of 11 have rated it as a Hold, with 7 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.21.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) trade information
Wall Street analysts have a consensus price target for the stock at $20.7, which means that the shares’ value could jump 31.35% from current levels. The projected low price target is $12 while the price target rests at a high of $36. In that case, then, we find that the current price level is +128.43% off the targeted high while a plunge would see the stock lose -23.86% from current levels.
Sangamo Therapeutics, Inc. (SGMO) estimates and forecasts
Figures show that Sangamo Therapeutics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +48.26% over the past 6 months, with this year growth rate of 7.06%, compared to 14.5% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are -625% and 18.9% for the next quarter. Revenue growth from the last financial year stood is estimated to be +20%.
10 analysts offering their estimates for the company have set an average revenue estimate of $31.44 Million for the current quarter. 6 have an estimated revenue figure of $21.24 Million for the next quarter concluding in March 01, 2021. Year-ago sales stood $54.85 Million and $13.08 Million respectively for this quarter and the next, and analysts expect sales will grow by -42.7% for the current quarter and 62.4% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -16.6% over the past 5 years. Earnings growth for 2021 is a modest -20.4%.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO)’s Major holders
Insiders own 17.6% of the company shares, while shares held by institutions stand at 58.44% with a share float percentage of 70.92%. Investors are also buoyed by the number of investors in a company, with Sangamo Therapeutics, Inc. having a total of 287 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 9.89 Million shares worth more than $93.48 Million. As of September 29, 2020, Blackrock Inc. held 6.99% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 8.13 Million shares as of September 29, 2020. The firm’s total holdings are worth over $76.8 Million and represent 5.75% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of December 30, 2020, the former fund manager holds about 2.84% shares in the company for having 4018225 shares of worth $62.7 Million while later fund manager owns 3.17 Million shares of worth $29.95 Million as of September 29, 2020, which makes it owner of about 2.24% of company’s outstanding stock.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.